Latest News
Proposed Federal Rule Would Create Chilling Effect on Future Research
In this issue:
- President's Corner
- Researcher Spotlight: Christelle Anaclet, PhD
- Early Success for Proposed New Method of Clearing Toxic Tau
- Is it Alzheimer's? What's Normal, What's Not
- And more!
Extracellular vesicles isolated from the blood of people with Down syndrome-related Alzheimer’s disease have been shown to seed toxic tau species in the brains of normal mice, shedding light on the uptake and transmission of toxic tau.
A pending Medicare decision could create a “chilling effect” on research.
Tau tangles tend to accumulate in brain cells that also express the Wolframin-1 protein—a discovery that’s been corroborated in human tissue and a mouse model.
Learn about a potential blood test to diagnose AD and monitor its progression and response to treatments.
People with Alzheimer’s pathology, but no significant cognitive decline (termed, resilient), have increases in synaptic signaling and energy production and decreased damage to waste clearance and anti-oxidant proteins when compared to people with AD-dementia.
Recent work from BrightFocus grantee Zhuohao He, PhD, advances knowledge of tau in Alzheimer’s disease and other neurodegeneration, and opens new avenues for drug development.
Neurodegeneration in a key brain region has been associated with sleep disturbances in people at risk for Alzheimer’s disease – a finding which could lead to earlier intervention and better treatment options.
